Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins

Laura Delgado-Soler1, Marta Pinto, Kaori Tanaka-Gil

  • 1Department of Physical Chemistry, University of Barcelona and the Institut de Recerca en Quimica Teorica i Computacional, Barcelona, Spain.

Insights

BH3 mimetics offer a promising cancer therapy strategy. This study reveals that the Bim(BH3) peptide binds all antiapoptotic proteins through primarily hydrophobic interactions, explaining its broad therapeutic potential.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Structural Biology

Background:

  • Proteins of the Bcl-2 family regulate apoptosis, a key process in cancer development and treatment resistance.
  • Overexpression of antiapoptotic proteins is linked to cancer progression and therapeutic resistance.
  • BH3 domain peptides can inhibit antiapoptotic proteins, making them promising cancer therapeutic candidates.

Purpose of the Study:

  • To elucidate the molecular mechanisms behind the pan-inhibition of antiapoptotic Bcl-2 proteins by the Bim(BH3) peptide.
  • To understand how Bim(BH3) achieves its broad binding affinity across different antiapoptotic proteins.

Main Methods:

  • Molecular modeling simulations using MM-PB/GBSA approaches.
  • Calculation of binding free energies for various Bim(BH3)-antiapoptotic protein complexes.
  • Identification of key peptide residues contributing to complex formation.

Main Results:

  • The binding of Bim(BH3) to pro-survival Bcl-2 proteins is predominantly driven by hydrophobic interactions.
  • Specific interactions contributing to binding are distributed throughout the Bim(BH3) peptide sequence.
  • This understanding provides insights into the design of selective or pan-inhibiting BH3 mimetics.

Conclusions:

  • The nonselective binding of Bim(BH3) is attributed to a combination of widespread hydrophobic interactions and distributed specific contacts.
  • These findings support the therapeutic potential of BH3 mimetics targeting antiapoptotic Bcl-2 proteins for cancer treatment.
  • The study highlights the importance of understanding binding determinants for optimizing BH3-mimetic drug design.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Conserved Binding Sites01:49

Conserved Binding Sites

Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally analyses the...